Anti-anxiety allergy medication sits at the intersection of two highly prevalent conditions in the UK: anxiety disorders and allergic disease. Many people manage both simultaneously, and understanding which treatments overlap — and how they interact — is essential for safe, effective care. Hydroxyzine, a first-generation antihistamine licensed by the MHRA for short-term anxiety in adults, is the most clinically significant example of this dual-purpose approach. This article explores how antihistamines may affect anxiety symptoms, the safety considerations around hydroxyzine, and how to access NHS support for both conditions.

Medications Used for Anxiety and Allergies in the UK

Anxiety is treated first-line with SSRIs and CBT per NICE CG113, while allergic conditions are managed primarily with second-generation antihistamines; some first-generation antihistamines overlap both areas.

In the UK, anxiety and allergic conditions are both highly prevalent, and it is not uncommon for individuals to be managing both simultaneously. The two conditions are treated through distinct pharmacological pathways, yet there is meaningful overlap in some of the medications used. Understanding how these treatments work — and how they may interact — is important for safe and effective care.

For anxiety, NICE guidance (CG113) recommends selective serotonin reuptake inhibitors (SSRIs) as first-line pharmacological treatment for generalised anxiety disorder (GAD), alongside psychological therapies such as cognitive behavioural therapy (CBT). It is important to note that whilst sertraline is widely used for GAD in UK practice, it is prescribed off-label for this indication; prescribers should obtain informed consent and document this accordingly. For short-term management during acute crises only, benzodiazepines may occasionally be considered, though NICE advises against their routine use due to the risk of dependence and withdrawal. Buspirone is licensed for anxiety in the UK but is not recommended by NICE for GAD and is rarely used in current UK practice.

For allergic conditions — including hay fever, urticaria, and allergic rhinitis — antihistamines are the cornerstone of treatment. These are broadly divided into:

• First-generation antihistamines (e.g., chlorphenamine, promethazine): sedating, cross the blood-brain barrier

• Second-generation antihistamines (e.g., cetirizine, loratadine, fexofenadine): non-sedating or minimally sedating, preferred for daytime use

NICE clinical knowledge summaries (CKS) for allergic rhinitis and urticaria, alongside NHS guidance, recommend second-generation antihistamines as first-line for allergic conditions due to their improved tolerability and reduced CNS effects. However, the sedating properties of first-generation antihistamines have led to their use — and in one case, formal licensing — in anxiety management, which forms the basis of the overlap explored throughout this article.

How Antihistamines May Affect Anxiety Symptoms

First-generation antihistamines can reduce anxiety-related tension by blocking central H1 receptors, but they are not recommended for anxiety disorders and carry significant anticholinergic and sedation risks.

The relationship between antihistamines and anxiety is rooted in their mechanism of action. Histamine is not only involved in allergic responses but also functions as a neurotransmitter in the central nervous system (CNS), playing a role in wakefulness, mood regulation, and arousal. First-generation antihistamines, by crossing the blood-brain barrier and blocking central H1 receptors, can produce sedation and a calming effect — properties that have attracted interest in anxiety management.

Some patients report that over-the-counter sedating antihistamines, such as promethazine or diphenhydramine (found in some sleep aids), temporarily reduce feelings of tension or restlessness. However, it is important to note that sedating antihistamines are not recommended for treating anxiety disorders and should not be used for this purpose without medical advice. They carry a significant anticholinergic burden — causing dry mouth, blurred vision, urinary retention, and cognitive impairment — and these risks are particularly pronounced in older adults. Next-day sedation and tolerance with repeated use are also recognised concerns. Individuals taking sedating antihistamines should avoid driving or operating machinery until they know how the medication affects them. Self-medicating with these products is not a substitute for evidence-based anxiety treatment and may mask symptoms that require proper assessment.

Conversely, some individuals with anxiety report that certain allergy symptoms — such as itching, skin flushing, or nasal congestion — can worsen their anxiety, creating a cycle of physical discomfort and psychological distress. In these cases, effectively treating the allergic condition may indirectly support anxiety management. It is also worth noting that anxiety itself can sometimes mimic or exacerbate allergic-type symptoms, making accurate diagnosis by a healthcare professional essential before commencing any treatment.

If you experience unexpected side effects from any antihistamine, you can report these via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Experiencing these side effects? Our pharmacists can help you navigate them →

Hydroxyzine: an Antihistamine Prescribed for Anxiety

Hydroxyzine is MHRA-licensed for short-term anxiety in adults at a maximum of 100 mg per day, but NICE does not recommend it for GAD; it also carries a risk of QT interval prolongation.

Hydroxyzine is a first-generation antihistamine that holds a unique position in UK clinical practice: it is licensed by the MHRA for the short-term treatment of anxiety in adults, in addition to its use for pruritus (itching) associated with allergic conditions. It is available in the UK under the brand name Atarax, among others.

In line with the MHRA Drug Safety Update (2015) and the UK Summary of Product Characteristics (SmPC), hydroxyzine should be used at the lowest effective dose for the shortest possible duration. For adults, the usual starting dose is 50 mg daily in divided doses, with a maximum of 100 mg per day. In elderly patients, hydroxyzine should be avoided where possible; if use is considered necessary, the maximum dose is 50 mg per day, given the increased risk of sedation, falls, and anticholinergic effects in this population.

Its anxiolytic effect is thought to arise primarily from H1 receptor antagonism in the CNS, producing sedation and reduced arousal. Additional pharmacological actions — including possible effects at serotonin, muscarinic, and adrenergic receptors — have been proposed, but the full mechanism is not completely elucidated.

It is important to clarify that NICE does not recommend hydroxyzine (or other sedating antihistamines) for GAD in its clinical guideline CG113. Its use for anxiety should therefore be guided by the MHRA SmPC, local prescribing policy, and individual clinical judgement, rather than NICE guidance.

Unlike benzodiazepines, hydroxyzine does not carry a risk of physical dependence or withdrawal, which may make it a useful short-term option for patients in whom benzodiazepines are contraindicated or undesirable.

Important safety considerations — QT interval prolongation: The MHRA has highlighted that hydroxyzine carries a risk of QT interval prolongation and Torsade de Pointes (a potentially serious cardiac arrhythmia). Hydroxyzine is contraindicated in patients with:

• Congenital or acquired QT prolongation

• Significant electrolyte disturbances (e.g., hypokalaemia, hypomagnesaemia)

• Clinically relevant bradycardia

Caution is required when hydroxyzine is used alongside other medicines that prolong the QT interval, including certain antidepressants (e.g., citalopram, escitalopram), antipsychotics, and some antibiotics. Prescribers should review the patient's full medication list before initiating treatment.

For patients with both anxiety and allergic conditions such as chronic urticaria, hydroxyzine may offer a dual benefit — addressing both the itch and the anxiety — under appropriate medical supervision. Prescribing decisions should always be individualised, taking into account the patient's full medical history, concurrent medications, and the nature and severity of their symptoms.

Risks, Side Effects and MHRA Safety Guidance

Key risks include sedation, anticholinergic effects, QT prolongation with hydroxyzine, and increased suicidal ideation in under-25s starting SSRIs; alcohol and CNS depressants must be avoided alongside sedating antihistamines.

As with all medications, both antihistamines and anxiolytics carry potential risks and side effects that patients and clinicians should be aware of. The MHRA regularly reviews the safety profiles of licensed medicines in the UK, and several important considerations apply to medications used across anxiety and allergy management.

Common side effects of sedating antihistamines and hydroxyzine include:

• Drowsiness and impaired concentration

• Dry mouth, blurred vision, and urinary retention (anticholinergic effects)

• Dizziness and impaired coordination — particularly relevant for older adults

• Paradoxical excitability, especially in children

• Next-day sedation with repeated use

MHRA restrictions specific to hydroxyzine:

• Adults: maximum 100 mg per day; use the lowest effective dose for the shortest duration

• Elderly patients: avoid if possible; if use is necessary, maximum 50 mg per day

• Contraindicated in patients with QT prolongation, significant electrolyte disturbances, or bradycardia

• Avoid concurrent use with other QT-prolonging medicines (e.g., citalopram, escitalopram, certain antipsychotics and antibiotics)

The MHRA has also issued guidance advising that first-generation antihistamines should not be used in children under 6 years for cough and cold symptoms, and caution is warranted across all age groups.

Interactions with CNS depressants: Patients should be advised to avoid alcohol when taking sedating antihistamines or hydroxyzine, as the combination significantly increases CNS depression. Concurrent use with other CNS depressants — including benzodiazepines and opioids — also increases the risk of sedation and respiratory depression and should be avoided or used only under close medical supervision. Driving or operating machinery should be avoided until the individual's response to the medication is known.

SSRIs used for anxiety: Common side effects include nausea, insomnia, and sexual dysfunction. There is a small but important risk of increased suicidal ideation in younger patients (particularly those under 25 years) during the early weeks of treatment — a risk highlighted in MHRA and NICE guidance. Patients in high-risk groups (e.g., under 25 years of age or with known suicide risk) should be reviewed within one week of initiating an SSRI; for other adults, review within two weeks of initiation is recommended. Clinicians should also monitor for early worsening of anxiety symptoms when starting SSRI treatment.

Not sure if this is normal? Chat with one of our pharmacists →

If you experience a suspected side effect from any medication, please report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Talking to Your GP About Anxiety and Allergy Treatment

Discussing both conditions with your GP allows safe co-management, avoidance of drug interactions, and access to referrals for specialist allergy or psychological therapy services including NHS Talking Therapies.

If you are experiencing symptoms of both anxiety and allergic conditions, it is important to discuss both with your GP rather than managing them independently or relying solely on over-the-counter remedies. A holistic assessment allows your doctor to identify any interactions between treatments and to tailor a management plan that addresses both conditions safely.

When speaking to your GP, it can be helpful to:

• Keep a symptom diary noting when anxiety and allergy symptoms occur, their severity, and any potential triggers

• List all current medications, including over-the-counter antihistamines, herbal remedies, and supplements

• Be open about any self-medication with sedating antihistamines for anxiety, as this is relevant to prescribing decisions

Your GP may refer you to a specialist — such as an allergist or immunologist for complex allergy presentations, or a psychiatrist or psychological therapies service for anxiety — depending on the severity of your symptoms. In England, NHS Talking Therapies (formerly IAPT) services offer CBT and other evidence-based psychological treatments for anxiety disorders, and self-referral is available in many areas without the need for a GP referral. If you live in Scotland, Wales, or Northern Ireland, equivalent services are available but may be accessed differently; your GP can advise on local referral pathways.

Seek emergency help immediately if you experience a severe allergic reaction (anaphylaxis), including throat swelling, difficulty breathing, or collapse. Call 999 without delay and use an adrenaline autoinjector (such as an EpiPen) if one has been prescribed to you. Do not wait to see if symptoms improve.

Also seek prompt medical advice if you experience:

• Worsening anxiety, low mood, or thoughts of self-harm — contact your GP, call NHS 111, or in a crisis contact the Samaritans on 116 123

• Unexpected or concerning side effects from any medication

Open communication with your healthcare team is the most effective way to ensure that both conditions are managed safely and in line with current NICE and NHS guidance.

NHS Resources and Next Steps for Managing Both Conditions

NHS Talking Therapies offers self-referral CBT for anxiety in England, while GP-led care and specialist allergy clinics manage allergic conditions; Every Mind Matters provides additional self-help tools.

The NHS offers a range of resources to support individuals managing anxiety and allergic conditions, and accessing the right services early can make a significant difference to quality of life. Understanding what is available — and how to navigate it — empowers patients to take an active role in their own care.

For anxiety, the following NHS pathways are available:

• NHS Talking Therapies (England only): self-referral psychological therapy services offering CBT, guided self-help, and other evidence-based interventions for anxiety and depression. If you live in Scotland, Wales, or Northern Ireland, speak to your GP about equivalent local services

• Every Mind Matters (NHS/UK Health Security Agency): an online platform offering personalised mental health action plans and self-help tools

• Urgent mental health support: if you need urgent help, contact NHS 111 and select the mental health option, or visit your local NHS trust website for details of your local crisis team. Availability of specific options (such as NHS 111 option 2) varies by area. The Samaritans can also be reached at any time on 116 123

For allergic conditions, the NHS provides:

• GP-led management for common allergies, including prescriptions for antihistamines, nasal corticosteroids, and referral for allergy testing where appropriate

• Referral to a specialist allergy clinic is typically considered for severe or uncontrolled allergic rhinitis despite optimal treatment, recurrent anaphylaxis, or refractory chronic urticaria or angioedema — in line with NICE CKS and BSACI guidance

• Specialist assessment for immunotherapy (desensitisation) where appropriate

• The Allergy UK charity website, which offers patient information and a helpline

Lifestyle measures — such as regular physical activity, adequate sleep, a balanced diet, and stress management techniques — can support both mental and physical wellbeing. NHS resources, including the Every Mind Matters platform, provide practical guidance on these approaches as helpful adjuncts to formal treatment.

If you are unsure where to start, your GP surgery remains the most appropriate first point of contact. They can coordinate your care, ensure your medications are reviewed regularly, and connect you with the most relevant NHS services for your individual needs. Remember to report any suspected medication side effects via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions